NewLimit is a company that invents medicines composed of epigenetic reprogramming factors that restore youthful function in old cells. They leverage functional assays, single cell multi-omics, and machine learning to reveal epigenetic features of aging and discover rejuvenating interventions. The company is composed of experts across cell biology, genomics, computational biology, machine learning, and operations. They collaborate across disciplines to design experiments and models that build upon each other. They work iteratively and move quickly to build technologies and generate enabling data. Each experiment informs the next.
However, they have announced that they will start by deeply interrogating epigenetic drivers of aging and developing products that can regenerate tissues to treat specific patient populations.
However, they have announced that they will start by deeply interrogating epigenetic drivers of aging and developing products that can regenerate tissues to treat specific patient populations.
Location: United States
Employees: 1-10
Total raised: $605M
Founded date: 2022
Founders name: Blake Byers; Jacob Kimmel
Investors 3
| Date | Name | Website |
| - | Dimension | dimensionc... |
| 11.09.2026 | age1 | age1.com |
| 05.12.2025 | Kivu Ventu... | kivu.vc/ |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.06.2026 | Series C | $435M | - |
| 16.05.2025 | Series B | $130M | - |
| 17.05.2023 | - | $40M | - |
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Blake | Byers | Co-Founder | linkedin.c... | - | b***e@newl... | - |
| - | Jacob | Kimmel | Co-founder... | linkedin.c... | - | j***b@newl... | - |
Mentions in press and media 20
| Date | Title | Description |
| 25.08.2026 | Индустрия долголетия привлекла миллиарды — теперь ее разработки проверяют на людях | Стартапы в сфере долголетия привлекли миллиарды долларов на разработки, призванные замедлить связанные со старением процессы. В ближайшие 12−18 месяцев несколько компаний планируют начать первые испытания на людях или представить ранние кли... |
| 24.07.2026 | Dimension Launches $800 Million Fund To Invest Across Science And Compute | Dimension announced the launch of Dimension III, an $800 million fund dedicated to investing alongside entrepreneurs working across the frontiers of science and compute. With the new fund in place, the firm now manages a total of $1.65 bill... |
| 09.06.2026 | NewLimit Grabs $435M Funding | SOUTH SAN FRANCISCO, CA. NewLimit, a biotechnology company, has closed a $435M Series C funding led by Founders Fund. >> Click here for more funding data on NewLimit >> To export NewLimit funding data to PDF and Excel, click he... |
| 08.06.2026 | NewLimit Raises $435 Million Series C To Bring Aging Reprogramming Medicine To Human Trials | NewLimit has announced a $435 million Series C led by Founders Fund, alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partne... |
| 03.06.2026 | NewLimit Raises $435M to Advance Longevity Medicine Trials | NewLimit Raises $435M to Accelerate Human Clinical Development NewLimit has raised $435 million in Series C funding to accelerate the development of medicines designed to treat age-related diseases. The round was led by Founders Fund. New i... |
| 02.06.2026 | New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells | Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected. The series C was led by longtime supporter Founders Fund, which was joined by fellow r... |
| 18.12.2025 | Giorgos Tsetis built Nutrafol into a $3.5 billion brand. Now he’s investing in AI and backing social causes | Nutrafol co-founder Giorgos Tsetis is ready for his second act after selling his stake in the hair growth supplements business to Unilever. Tsetis, who has backed xAI, Anthropic and SpaceX, has launched a family office to continue investing... |
| 21.10.2025 | NewLimit Raises $45 Million Funding to Advance Longevity Research | NewLimit Secures $45 Million Funding for Longevity Breakthrough Longevity research company NewLimit has raised $45 million in new funding to support its mission of reversing cellular ageing. The round includes Lilly Ventures, Duke Universit... |
| 20.05.2025 | Sam Altman-Backed Startup Aims to Add 10 Years to Human Life Through Stem Cell Tech | OpenAI’s Sam Altman has poured millions into the longevity-focused Retro Biosciences. Sean Gallup/Getty Images The average American can expect to live about 77 years, according to the Centers for Disease Control and Prevention. Retro Biosci... |
| 16.05.2025 | NewLimit Lands $130M Series B Funding | SOUTH SAN FRANCISCO, CA, Longevity startup, NewLimit, has raised a $130 million Series B round led by Kleiner Perkins >> Click here for more funding data on NewLimit >> To export NewLimit funding data to PDF and Excel, click he... |
Show more